Heart Test Laboratories, Inc. Share Price
Equities
HSCS
US42254E3027
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.97 USD | -38.37% | -20.80% | -59.24% |
Sales 2024 * | 59.3K 4.67M | Sales 2025 * | 1.9M 150M | Capitalization | 4.57M 360M |
---|---|---|---|---|---|
Net income 2024 * | -6M -472M | Net income 2025 * | -9M -709M | EV / Sales 2024 * | 77.1 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.41 x |
P/E ratio 2024 * |
-0.35
x | P/E ratio 2025 * |
-0.66
x | Employees | 12 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.99% |
1 day | -38.37% | ||
1 week | -20.80% | ||
Current month | -24.57% | ||
1 month | -30.99% | ||
3 months | -44.99% | ||
6 months | -57.94% | ||
Current year | -59.24% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Simpson
CEO | Chief Executive Officer | 55 | 24/07/13 |
Danielle Watson
DFI | Director of Finance/CFO | 42 | 31/10/21 |
Aaron Peterson
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Hilz
COO | Chief Operating Officer | 66 | 24/07/13 |
David R. Wells
BRD | Director/Board Member | 61 | 27/12/22 |
Andrew Simpson
CEO | Chief Executive Officer | 55 | 24/07/13 |
Date | Price | Change | Volume |
---|---|---|---|
17/05/24 | 6.97 | -38.37% | 347,903 |
16/05/24 | 11.31 | +25.81% | 411,195 |
15/05/24 | 8.99 | +13.65% | 74,210 |
14/05/24 | 7.91 | +12.04% | 31,975 |
13/05/24 | 7.06 | -19.77% | 53,607 |
Delayed Quote Nasdaq, May 17, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-59.24% | 7.42M | |
-11.41% | 3.07B | |
+4.27% | 190M | |
-14.72% | 84.6M | |
+13.04% | 52.99M |
- Stock Market
- Equities
- HSCS Stock